Raymond James Financial
ZVRA icon

Raymond James Financial’s Zevra Therapeutics ZVRA Stock Holding History

Raymond James Financial’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Sell
19,040
-4,191
-18% -$46.6K ﹤0.01% 4870
2026
Q1 		$217K Sell
23,231
-2,420
-9% -$21.8K ﹤0.01% 4850
2025
Q4 		$230K Buy
25,651
+2,345
+10% +$22.2K ﹤0.01% 4725
2025
Q3 		$222K Sell
23,306
-3,610
-13% -$36.2K ﹤0.01% 4576
2025
Q2 		$237K Hold
26,916
– – ﹤0.01% 4431
2025
Q1 		$202K Hold
26,916
– – ﹤0.01% 4425
2024
Q4 		$224K Buy
+26,916
New +$230K ﹤0.01% 4339

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial's ZVRA Position: Q2 2026 in Review

Raymond James Financial reduced its Zevra Therapeutics (ZVRA) stake by 18% in Q2 2026, selling an estimated $46.6K and leaving 19,040 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #4870.

Raymond James Financial first reported a position in ZVRA in Q4 2024 and has held it in 7 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Raymond James Financial held 19,040 shares of Zevra Therapeutics worth $273K as of Q2 2026.
  • Raymond James Financial sold 4,191 Zevra Therapeutics shares in Q2 2026, an estimated $46.6K.
  • Zevra Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4870 holding.
  • Raymond James Financial first reported a position in Zevra Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.